ARCHIVES

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Congress Cuts $210 Million From NIH Budget For The Remainder of 2011

April 15, 2011

Breast Cancer Funding: Shalala Approves Agreement Over Disputed $14 Million

August 8, 1997

Studies Link Age-Dependent Outcome To Immune Cells

November 28, 2003

Proposed DRG Regulations Would Limit Exemptions To Fox Chase, M.D. Anderson; In Effect Oct. 1

September 9, 1983

Drug Effectiveness Weakens After Three Years, Study Says

May 27, 2011

Committee Approves NDA For Tamoxifen

January 21, 1977